Trifluoperazine Synergistically Potentiates Bortezomib-Induced Anti-Cancer Effect in Multiple Myeloma via Inhibiting P38 MAPK/NUPR1.

Jing, Zizi; Yu, Wei; Li, Anmao; Chen, Xuanxin; Chen, Yuying; Chen, Jianbin

Jing, Zizi; Yu, Wei; Li, Anmao; Chen, Xuanxin; Chen, Yuying; Chen, Jianbin.

Afiliação

Jing Z; Department of Hematology, The First Affiliated Hospital of Chongqing Medical University.
Yu W; Department of Hematology, The First Affiliated Hospital of Chongqing Medical University.
Li A; Department of Respiratory, The First Affiliated Hospital of Chongqing Medical University.
Chen X; Department of Hematology, The First Affiliated Hospital of Chongqing Medical University.
Chen Y; Department of Hematology, The First Affiliated Hospital of Chongqing Medical University.
Chen J; Department of Hematology, The First Affiliated Hospital of Chongqing Medical University.

Tohoku J Exp Med ; 257(4): 315-326, 2022 Jul 22.

Article em En | MEDLINE | ID: mdl-35644544

Assuntos

Antineoplásicos; Mieloma Múltiplo; Antineoplásicos/farmacologia; Antineoplásicos/uso terapêutico; Apoptose; Fatores de Transcrição Hélice-Alça-Hélice Básicos/metabolismo; Bortezomib/farmacologia; Bortezomib/uso terapêutico; Linhagem Celular Tumoral; Proliferação de Células; Humanos; Mieloma Múltiplo/tratamento farmacológico; Proteínas de Neoplasias/metabolismo; Trifluoperazina/farmacologia; Trifluoperazina/uso terapêutico; Proteínas Quinases p38 Ativadas por Mitógeno/metabolismo

Palavras-chave

apoptosis; bortezomib; cell cycle; multiple myeloma; trifluoperazine

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Mieloma Múltiplo / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Tohoku J Exp Med Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google